title: Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma.
abstract: BACKGROUND
  Recent studies have demonstrated that lesions of aortic sclerosis and stenosis share several similarities with lesions of atherosclerosis. In atherosclerosis, angiotensin-converting enzyme (ACE) is expressed by a subset of macrophages. This study was undertaken to determine whether ACE might be present in aortic sclerosis or stenosis lesions.
  
  
  RESULTS
  Immunohistochemistry was performed on 26 paraffin-embedded human aortic valves. Monospecific antibodies were used to identify ACE, macrophages, angiotensin II type 1 receptor (AT-1 receptor), angiotensin II, and apolipoprotein B. Human low-density lipoprotein (LDL) and high-density lipoprotein (HDL) were isolated from plasma of normal volunteers by sequential density-gradient ultracentrifugation. ACE was not present in normal valves but was present in all valves with aortic sclerosis or stenosis lesions. ACE was detected on a subset of lesion macrophages but was present primarily in an extracellular distribution, where it colocalized with apolipoprotein B. ACE was detected by Western blotting on plasma LDL but not on HDL isolated from normal volunteers. Angiotensin II, the enzymatic product of ACE, was colocalized with ACE in valve lesions. ACE also was colocalized with apolipoprotein B in an adjacent coronary atherosclerotic plaque.
  
  
  CONCLUSIONS
  ACE is present in aortic sclerosis and stenosis lesions, where it may participate in lesion development, as is evidenced by the presence of its enzymatic product, angiotensin II. The observation of an association of ACE with LDL in both lesions and plasma suggests that LDL may deliver ACE to lesions and has implications for the role of ACE-containing LDL in other diseases, such as atherosclerosis.
authors.affiliation: Division of Cardiology, University of Washington, Seattle 98195-6422, USA. cardiac@u.washington.edu
authors.forename: Kevin D
authors.initials: KD
authors.lastname: O'Brien
authors.forename: David M
authors.initials: DM
authors.lastname: Shavelle
authors.forename: Michael T
authors.initials: MT
authors.lastname: Caulfield
authors.forename: Thomas O
authors.initials: TO
authors.lastname: McDonald
authors.forename: Katherine
authors.initials: K
authors.lastname: Olin-Lewis
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Otto
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Probstfield
mesh_terms: D000804:Angiotensin II / Q000032:analysis / Q000276:immunology; D001021:Aortic Valve / Q000737:chemistry / Q000201:enzymology / Q000473:pathology*; D001024:Aortic Valve Stenosis / Q000097:blood / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology*; D001055:Apolipoproteins B / Q000032:analysis / Q000276:immunology; D003324:Coronary Artery Disease / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D008077:Lipoproteins, LDL / Q000097:blood / Q000737:chemistry*; D007703:Peptidyl-Dipeptidase A / Q000032:analysis* / Q000097:blood / Q000276:immunology; D044140:Receptor, Angiotensin, Type 1; D011945:Receptors, Angiotensin / Q000032:analysis / Q000276:immunology; D012598:Sclerosis
chemical_list: D001055:Apolipoproteins B; D008077:Lipoproteins, LDL; D044140:Receptor, Angiotensin, Type 1; D011945:Receptors, Angiotensin; D000804:Angiotensin II; D007703:Peptidyl-Dipeptidase A